Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

In the highly competitive biotech industry, only a few standout companies attract Wall Street’s attention. Among them, two ...

DelveInsight's THR-β Agonist Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $60.0 for Viking Therapeutics, spanning the last three ...

Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen a notable 7.76% ...

Viking Therapeutics reported a solid financial standing with $808 million in cash, cash equivalents, and short-term investments. This strong cash position provides a substantial financial runway to ...

In addition to Stifel Nicolaus, Viking Therapeutics also received a Buy from William Blair’s Andy Hsieh in a report issued today. However, yesterday, Citi maintained a Hold rating on Viking ...

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

We bring you an exclusive behind-the-scenes look at this iconic mission with Dr Linda Spilker, from her first job out of ...